Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

LGND Relative to the S&P 500

LGND Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Ligand Pharmaceuticals Inc. (NASD:LGND) seasonal charts above shows that a Buy Date of January 24 and a Sell Date of April 27 has resulted in a geometric average return of 6.66% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 8.29% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand’s business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company’s revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

To download LGND seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: LGND